1st Aug 2016 11:40
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
Verona Pharma PLC | ||
2 Reason for the notification (please tick the appropriate box or boxes): | |||
An acquisition or disposal of voting rights |
X | ||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||
An event changing the breakdown of voting rights | |||
Other (please specify): | |||
3. Full name of person(s) subject to the notification obligation: iii |
OrbiMed Private Investments VI, LP | ||
4. Full name of shareholder(s) (if different from 3.):iv | |||
5. Date of the transaction and date on which the threshold is crossed or reached: v |
July 29, 2016 | ||
6. Date on which issuer notified: |
July 28, 2016 | ||
7. Threshold(s) that is/are crossed or reached: vi, vii |
Greater than 5% ownership | ||
8. Notified details: | |||||||
A: Voting rights attached to shares viii, ix | |||||||
Class/type of shares
if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||
Direct |
Direct xi | Indire ct xii |
Direct |
Indirect | |||
GB00B06GSH43 |
0 |
0 |
233,492,342 |
233,492,342 |
0 |
9.10% |
0 |
B: Qualifying Financial Instruments | ||||
Resulting situation after the triggering transaction | ||||
Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights |
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | |
Nominal |
Delta | |||||
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
233,492,342 |
9.10% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
|
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), is the sole managing member of GP VI. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors.
|
Proxy Voting: | |
10. Name of the proxy holder: | |
11. Number of voting rights proxy holder will cease to hold: | |
12. Date on which proxy holder will cease to hold voting rights: |
13. Additional information: | |
14. Contact name: |
Douglas Coon |
15. Contact telephone number: |
212-739-6400 |
Related Shares:
VRP.L